Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (VKTX)
NASDAQ:VKTX
Holding VKTX?
Track your performance easily
Earnings Data
Report Date
Feb 05, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.27Last Year’s EPS
-0.25Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2018
|% Change Since: -46.08%
|Next Earnings Date:Aug 09, 2018
Earnings Call Sentiment|Neutral
Viking Therapeutics demonstrated significant progress with their clinical programs and strong financial positioning, although increased expenses and pending regulatory approvals present challenges. The overall sentiment is balanced by these factors.Company Guidance
During the Viking Therapeutics Q3 2024 earnings call, the executives provided extensive updates on their clinical programs and financial performance. Key highlights included reporting positive data from multiple trials: the Phase II VENTURE trial for VK2735 demonstrated up to 14.7% weight loss in obesity patients, while the VOYAGE study for VK2809 showed significant improvements in liver histology for NASH and fibrosis. Additionally, the Phase Ib trial of VK0214 in X-ALD patients revealed reductions in very long chain fatty acids. Financially, Viking's R&D expenses rose to $22.8 million from $18.4 million year-over-year due to increased drug manufacturing and regulatory costs, contributing to a net loss of $24.9 million. The company maintained a robust cash position of $930 million, signaling strong financial health to support future clinical milestones.Positive Clinical Trial Results
Viking Therapeutics reported positive data from four clinical programs, including the Phase II VENTURE trial for VK2735 showing up to 14.7% weight loss and the Phase IIb VOYAGE study for VK2809 demonstrating significant improvements in NASH resolution and fibrosis.
Financial Health
Viking holds cash, cash equivalents, and short-term investments of $930 million as of September 30, 2024, compared to $362 million as of December 31, 2023, indicating strong financial backing to support future clinical milestones.
Advancement of VK2735
VK2735 is moving into Phase III development for obesity, following a Type C meeting with the FDA. Viking plans to initiate a Phase III study after an end of Phase II meeting with the agency.
Pipeline Expansion
Viking announced a new internally developed amylin agonist program for obesity treatment and plans to initiate clinical trials in 2025.
---
VKTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VKTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 23, 2024 | $60.39 | $73.22 | +21.25% |
| Jul 24, 2024 | $50.41 | $64.68 | +28.31% |
| Apr 24, 2024 | $65.07 | $68.86 | +5.82% |
| Feb 07, 2024 | $24.48 | $28.89 | +18.01% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Viking Therapeutics (VKTX) report earnings?
Viking Therapeutics (VKTX) is schdueled to report earning on Feb 05, 2025, TBA Not Confirmed.
What is Viking Therapeutics (VKTX) earnings time?
Viking Therapeutics (VKTX) earnings time is at Feb 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VKTX EPS forecast?
VKTX EPS forecast for the fiscal quarter 2024 (Q4) is -0.27.
---